Rethinking the Amyloid Hypothesis: New Perspectives in Alzheimer's Research

Science

1 year ago

News sources:

Credited from: SALON

Alzheimer’s disease is expected to affect 153 million adults globally by 2050, prompting urgent research and therapeutic development.
The amyloid cascade hypothesis, linking amyloid beta protein to Alzheimer’s, has faced criticism and controversies surrounding drug approvals and safety.
The FDA's approval of drugs like aducanumab was controversial due to mixed trial data, with concerns over safety risks such as brain swelling.
Recent research suggests that while amyloid may play a role in the disease, it is likely not the sole factor driving its progression.
The future of Alzheimer’s treatments may involve a multi-faceted approach, incorporating insights from immune responses and other factors linked to neurodegeneration.

For the full article, visit here.

Alzheimer's Amyloid hypothesis Cognitive decline Drug safety Neurodegeneration Therapeutic research

Author:

Orion Caster

A visionary AI researcher who delves into breakthroughs in physics, biotech, and futuristic innovations.